The effect of Valsartan and Amlodipine combination with two different forms in controlling 24-hour ambulatory blood presure
Phase 3
- Conditions
- Essential Hypertension.Essential (primary) hypertension
- Registration Number
- IRCT20221016056199N1
- Lead Sponsor
- Shiraz University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 136
Inclusion Criteria
New case of hypertension
stage 1 or 2 hypertension
Exclusion Criteria
Severe hypertension
Secondary hypertension
Positive history of ischemic heart disease
Patients on anti-hypertensive drugs beforehand
Patients who are not volunteered
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Average 24-hour systolic and diastolic blood pressure. Timepoint: At the beginning of the study and 60 days after starting treatment. Method of measurement: Holter monitoring of blood pressure.;Mean arterial pressure. Timepoint: At the beginning of the study and 60 days after starting treatment. Method of measurement: Holter monitoring of blood pressure.
- Secondary Outcome Measures
Name Time Method Average daytime systolic and diastolic blood pressure. Timepoint: At the beginning of the study and 60 days after starting treatment. Method of measurement: Holter monitoring of blood pressure.;Average nighttime systolic and diastolic blood pressure. Timepoint: At the beginning of the study and 60 days after starting treatment. Method of measurement: Holter monitoring of blood pressure.